Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656195 | 0.81 | ALDH1A1 (0.34) | SCN10APTGESALOX5TP53TSHR | |
| SCHEMBL21206330 | 0.76 | ALOX5 (0.47) | PTGESALOX5 | |
| SCHEMBL10163618 | 0.71 | GRIN2C (0.40) | SCN10ATRPV1 | |
| SCHEMBL10132023 | 0.70 | ALDH1A1 (0.39) | SCN10ATSHRTRPV1 | |
| SCHEMBL23621474 | 0.70 | GRIA4 (0.37) | SCN10AGRIA4 | |
| SCHEMBL25101045 | 0.69 | ADAM17 (0.42) | SCN10AGRIA4 | |
| SCHEMBL8279312 | 0.69 | TSHR (0.38) | SCN10ATSHRTRPV1 | |
| SCHEMBL15912366 | 0.68 | DHPS (0.36) | SCN10APTGESALOX5TP53TSHR | |
| SCHEMBL25101058 | 0.68 | SCN10A (0.45) | SCN10AGRIA4 | |
| SCHEMBL16482576 | 0.67 | ALDH1A1 (0.36) | SCN10ATSHRHSP90AA1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591341-B2 | Bicyclic and tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591341-B2 | Bicyclic and tricyclic compounds | SLC10A1, PKD1, CYP11B2 | SCN10A 586/4885GRIA4 3783/4885PTGES 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.